TPST-1120 is under clinical development by Tempest Therapeutics and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase I drugs for Hepatocellular Carcinoma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TPST-1120’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TPST-1120 overview
TPST-1120 is under development for the treatment of solid tumors including castration resistant prostate cancer, liposarcoma and leiomyosarcoma, cholangiocarcinoma, gastro-esophageal cancer, head and neck cancer, hepatocellular carcinoma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, renal cell carcinoma, triple-negative breast cancer, urothelial cancer, sarcoma, MSS colorectal cancer and hematological tumor (hemonc). It is a first in class small molecule acts by targeting peroxisome proliferator activated receptor alpha (PPAR alpha). It is administered through oral route.
Tempest Therapeutics overview
Tempest Therapeutics (Tempest), formerly Millendo Therapeutics, Inc. is a biotechnology company. It develops small molecule medicines that regulate anti-tumor immunity pathways. The company’s pipeline portfolio includes TPST-1495, an IDO (enzyme) inhibitor that generates kynurenine, a powerful immunosuppressive factor, which regulates immune cells in the tumor microenvironment (TME) and blocks anti-tumor immunity; TPST-1120, an antagonist that acts against peroxisome proliferator-activated receptor alpha (PPARa); and E-prostanoid (EP) receptor antagonists whose prostaglandin E2 (PGE2) pathway facilitates immune suppression in the TME. Tempest develops an orally available inhibitor of TREX-1 designed to activate cGAS/STING pathway, for the development of anti-tumor immunity. TempestTx is headquartered in Brisbane, California, the US.
For a complete picture of TPST-1120’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
